Cyproterone, an anti-androgen, is used in combination with estrogen for the therapy of hirsutism and severe acne in females and as a palliative in prostatic carcinoma.
A-849519 is a reversible inhibitor of MetAP2 that has demonstrated anti-angiogenesis and anticancer activity in a number of in vitro and in vivo models. In this study, we evaluated the anticancer activity of A-849519 in a modified Dunning model of androgen-independent prostate cancer and compared its efficacy with TNP-470, an established MetAP2 inhibitor.